These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

932 related items for PubMed ID: 30265679

  • 1. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL, Moss JA, Marzinke MA, Hendrix CW, Anton PA, Pyles RB, Guthrie KM, Dawson L, Olive TJ, Butkyavichene I, Churchman SA, Cortez JM, Fanter R, Gunawardana M, Miller CS, Yang F, Rosen RK, Vargas SE, Baum MM.
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [Abstract] [Full Text] [Related]

  • 2. Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc.
    Vincent KL, Moss JA, Marzinke MA, Hendrix CW, Anton PA, Gunawardana M, Dawson LN, Olive TJ, Pyles RB, Baum MM.
    PLoS One; 2018 Sep; 13(8):e0201952. PubMed ID: 30133534
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.
    Moss JA, Srinivasan P, Smith TJ, Butkyavichene I, Lopez G, Brooks AA, Martin A, Dinh CT, Smith JM, Baum MM.
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5125-35. PubMed ID: 24936594
    [Abstract] [Full Text] [Related]

  • 4. Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model.
    Moss JA, Butkyavichene I, Churchman SA, Gunawardana M, Fanter R, Miller CS, Yang F, Easley JT, Marzinke MA, Hendrix CW, Smith TJ, Baum MM.
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3759-66. PubMed ID: 27067321
    [Abstract] [Full Text] [Related]

  • 5. An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.
    Baum MM, Butkyavichene I, Churchman SA, Lopez G, Miller CS, Smith TJ, Moss JA.
    Int J Pharm; 2015 Nov 10; 495(1):579-587. PubMed ID: 26386138
    [Abstract] [Full Text] [Related]

  • 6. User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: A mixed methods study of acceptability and use experiences.
    Guthrie KM, Rosen RK, Vargas SE, Getz ML, Dawson L, Guillen M, Ramirez JJ, Baum MM, Vincent KL.
    PLoS One; 2018 Nov 10; 13(5):e0197269. PubMed ID: 29758049
    [Abstract] [Full Text] [Related]

  • 7. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
    Keller MJ, Mesquita PM, Marzinke MA, Teller R, Espinoza L, Atrio JM, Lo Y, Frank B, Srinivasan S, Fredricks DN, Rabe L, Anderson PL, Hendrix CW, Kiser PF, Herold BC.
    AIDS; 2016 Mar 13; 30(5):743-51. PubMed ID: 26605514
    [Abstract] [Full Text] [Related]

  • 8. Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV Exposures.
    Srinivasan P, Moss JA, Gunawardana M, Churchman SA, Yang F, Dinh CT, Mitchell JM, Zhang J, Fanter R, Miller CS, Butkyavichene I, McNicholl JM, Smith TJ, Baum MM, Smith JM.
    PLoS One; 2016 Mar 13; 11(6):e0157061. PubMed ID: 27275923
    [Abstract] [Full Text] [Related]

  • 9. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
    Wang X, Nwokolo N, Korologou-Linden R, Hill A, Whitlock G, Day-Weber I, McClure MO, Boffito M.
    HIV Med; 2018 Jan 13; 19(1):1-6. PubMed ID: 28657199
    [Abstract] [Full Text] [Related]

  • 10. Genital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral Administration.
    Ouattara LA, Thurman AR, Jacot TA, Cottrell M, Sykes C, Blake K, Fang X, Ju S, Vann NC, Schwartz J, Doncel GF.
    J Acquir Immune Defic Syndr; 2022 Jan 01; 89(1):87-97. PubMed ID: 34878438
    [Abstract] [Full Text] [Related]

  • 11. Acceptability of a Tenofovir Disoproxil Fumarate Intravaginal Ring for HIV Pre-Exposure Prophylaxis Among Sexually Active Women.
    Dobkin A, McWalters J, Barnett R, Ray LL, Espinoza L, McGinn AP, Atrio JM, Keller MJ.
    Sex Transm Dis; 2020 Dec 01; 47(12):819-824. PubMed ID: 33186337
    [Abstract] [Full Text] [Related]

  • 12. The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM.
    McGowan I, Wilkin T, Landovitz RJ, Wu C, Chen Y, Marzinke MA, Hendrix CW, Richardson P, Eshleman SH, Andrade A, Chege W, Anderson PL, McCauley M, Farley J, Mayer KH, Anton P, Brand RM, Cranston RD, Gulick R.
    AIDS; 2019 Feb 01; 33(2):237-246. PubMed ID: 30557160
    [Abstract] [Full Text] [Related]

  • 13. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.
    Thurman AR, Schwartz JL, Brache V, Clark MR, McCormick T, Chandra N, Marzinke MA, Stanczyk FZ, Dezzutti CS, Hillier SL, Herold BC, Fichorova R, Asin SN, Rollenhagen C, Weiner D, Kiser P, Doncel GF.
    PLoS One; 2018 Feb 01; 13(6):e0199778. PubMed ID: 29953547
    [Abstract] [Full Text] [Related]

  • 14. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
    Mugwanya KK, Hendrix CW, Mugo NR, Marzinke M, Katabira ET, Ngure K, Semiyaga NB, John-Stewart G, Muwonge TR, Muthuri G, Stergachis A, Celum CL, Baeten JM.
    PLoS Med; 2016 Sep 01; 13(9):e1002132. PubMed ID: 27676257
    [Abstract] [Full Text] [Related]

  • 15. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.
    Shieh E, Marzinke MA, Fuchs EJ, Hamlin A, Bakshi R, Aung W, Breakey J, Poteat T, Brown T, Bumpus NN, Hendrix CW.
    J Int AIDS Soc; 2019 Nov 01; 22(11):e25405. PubMed ID: 31692269
    [Abstract] [Full Text] [Related]

  • 16. Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review.
    Wu L, Niu X, Brunelli MK, Mugwanya KK.
    Curr HIV/AIDS Rep; 2024 Oct 01; 21(5):264-281. PubMed ID: 39120667
    [Abstract] [Full Text] [Related]

  • 17. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
    Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, Ramirez-Cardich ME, Namwongprom S, Chodacki P, de Mendonca LM, Wang F, Lama JR, Chariyalertsak S, Guanira JV, Buchbinder S, Bekker LG, Schechter M, Veloso VG, Grant RM, Preexposure Prophylaxis Initiative Study Team.
    Clin Infect Dis; 2015 Aug 15; 61(4):572-80. PubMed ID: 25908682
    [Abstract] [Full Text] [Related]

  • 18. Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial.
    Thurman AR, Schwartz JL, Cottrell ML, Brache V, Chen BA, Cochón L, Ju S, McGowan I, Rooney JF, McCallister S, Doncel GF.
    EClinicalMedicine; 2021 Jun 15; 36():100893. PubMed ID: 34041459
    [Abstract] [Full Text] [Related]

  • 19. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM, Mellors JW.
    Curr Opin HIV AIDS; 2016 Jan 15; 11(1):49-55. PubMed ID: 26633640
    [Abstract] [Full Text] [Related]

  • 20. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
    Thurman AR, Schwartz JL, Ravel J, Gajer P, Marzinke MA, Yousefieh N, Anderson SM, Doncel GF.
    PLoS One; 2019 Jan 15; 14(5):e0217229. PubMed ID: 31107913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.